as 05-09-2025 12:47pm EST
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Founded: | 2022 | Country: | United States |
Employees: | N/A | City: | LA JOLLA |
Market Cap: | 76.6M | IPO Year: | N/A |
Target Price: | $14.67 | AVG Volume (30 days): | 333.9K |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.72 | EPS Growth: | N/A |
52 Week Low/High: | $0.97 - $6.35 | Next Earning Date: | 05-08-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ZURA Breaking Stock News: Dive into ZURA Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Simply Wall St.
15 days ago
Simply Wall St.
a month ago
Business Wire
a month ago
Business Wire
3 months ago
Simply Wall St.
4 months ago
Business Wire
5 months ago
Business Wire
5 months ago
The information presented on this page, "ZURA Zura Bio Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.